OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
OPKO Health expanded its partnership with Nicoya Therapeutics to commercialize RAYALDEE in Greater China, securing a 15% equity stake in Nicoya in exchange for revised royalty terms. The companies anticipate regulatory approvals for the treatment in China and related territories in 2027, targeting a market with over 20 million adults affected by stage 3 or 4 chronic kidney disease.
Key figures
- Deal Value Usd
- 115000000
- Target market patients
- 20000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.